Development and application of ‘phosphoflow’ as a tool for immunomonitoring

References

• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science305(5681), 200–205 (2004).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol.10(1), 11–23 (2009).
   PubMedGoogle Scholar
• Britten CM, Gouttefangeas C, Welters MJ et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother.57(3), 289–302 (2008).
   PubMed Web of Science ®Google Scholar
• Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Int. Rev. Immunol.22(3–4), 283–319 (2003).
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods294(1–2), 15–22 (2004).
   PubMed Web of Science ®Google Scholar
• Devevre E, Romero P, Mahnke YD. LiveCount assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry. J. Immunol. Methods311(1–2), 31–46 (2006).
   PubMedGoogle Scholar
• He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in targeT cells. J. Immunol. Methods304(1–2), 43–59 (2005).
   PubMedGoogle Scholar
• Smith -Garvin JE, Koretzky GA, Jordan MS. T cell activation. Ann. Rev. Immunol.27, 591–619 (2009).
   PubMedGoogle Scholar
• Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Ann. Rev. Immunol.28, 21–55 (2010).
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J. Immunol.177(3), 1581–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin. Immunol.110(3), 206–221 (2004).
   PubMed Web of Science ®Google Scholar
• Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat. Biotechnol.20(2), 155–162 (2002).
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Tibes R, Qiu YH et al. Functional proteomic profiling of AML predicts response and survival. Blood113(1), 154–164 (2009).
   PubMed Web of Science ®Google Scholar
• Tsavachidou-Fenner D, Tannir N, Tamboli P et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann. Oncol. DOI: 10.1093/annonc/mdp600 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Marodi L, GodaK, Palicz A, Szabo G. Cytokine receptor signalling in neonatal macrophages: defective STAT-1 phosphorylation in response to stimulation with IFN-γ. Clin. Exp. Immunol.126(3), 456–460 (2001).
   Google Scholar
• Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin. Immunol.90(3), 425–430 (1999).
   PubMedGoogle Scholar
• Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of intracellular phosphorylated STAT-4 by flow cytometry. Clin. Immunol.100(3), 270–276 (2001).
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Cappellini A, Bortul R et al. Flow cytometric detection of total and serine 473 phosphorylated Akt. J. Cell. Biochem.86(4), 704–715 (2002).
   PubMedGoogle Scholar
• Perez OD, Kinoshita S, Hitoshi Y et al. Activation of the PKB/AKT pathway by ICAM-2. Immunity16(1), 51–65 (2002).
   PubMed Web of Science ®Google Scholar
• Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry46(2), 72–78 (2001).
   PubMedGoogle Scholar
• Zell T, Khoruts A, Ingulli E, Bonnevier JL, Mueller DL, Jenkins MK. Single-cell analysis of signal transduction in CD4 T cells stimulated by antigen in vivo. Proc. Natl Acad. Sci. Am.98(19), 10805–10810 (2001).
   PubMedGoogle Scholar
• Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A55(2), 61–70 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science298(5600), 1911–1912 (2002).
   PubMed Web of Science ®Google Scholar
• Aaronson DS, Horvath CM. A road map for those who don’t know JAK-STAT. Science296(5573), 1653–1655 (2002).
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene285(1–2), 1–24 (2002).
   PubMed Web of Science ®Google Scholar
• Lamvik J, Hella H, Liabakk NB, Halaas O. Nonlabeled secondary antibodies augment/maintain the binding of primary, specific antibodies to cell membrane antigens. Cytometry45(3), 187–193 (2001).
   PubMedGoogle Scholar
• Ebo DG, Dombrecht EJ, Bridts CH, Aerts NE, de Clerck LS, Stevens WJ. Combined analysis of intracellular signalling and immunophenotype of human peripheral blood basophils by flow cytometry: a proof of concept. Clin. Exp. Allergy37(11), 1668–1675 (2007).
   PubMed Web of Science ®Google Scholar
• Montag DT, Lotze MT. Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells. J. Immunol. Methods313(1–2), 48–60 (2006).
   PubMedGoogle Scholar
• Krutzik PO, Clutter MR, Nolan GP. Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry. J. Immunol.175(4), 2357–2365 (2005).
   PubMedGoogle Scholar
• Perez OD, Mitchell D, Campos R, Gao GJ, Li L, Nolan GP. Multiparameter analysis of intracellular phosphoepitopes in immunophenotyped cell populations by flow cytometry. Curr. Protoc. Cytom.6(6), 20 (2005).
   PubMedGoogle Scholar
• Schulz KR, Danna EA, Krutzik PO, Nolan GP. Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol.8(8), 17 (2007).
   PubMedGoogle Scholar
• Perez OD, Krutzik PO, Nolan GP. Flow cytometric analysis of kinase signaling cascades. Methods Mol. Biol.263, 67–94 (2004).
   PubMedGoogle Scholar
• Firaguay G, Nunes JA. Analysis of signaling events by dynamic phosphoflow cytometry. Sci. Signal.2(86), pl3 (2009).
   PubMed Web of Science ®Google Scholar
• Perez OD, Mitchell D, Jager GC et al. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat. Immunol.4(11), 1083–1092 (2003).
   PubMed Web of Science ®Google Scholar
• Krutzik PO, Hale MB, Nolan GP. Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J. Immunol.175(4), 2366–2373 (2005).
   PubMed Web of Science ®Google Scholar
• Kostianovsky AM, Maier LM, Baecher-Allan C, Anderson AC, Anderson DE. Up-regulation of gene related to anergy in lymphocytes is associated with Notch-mediated human T cell suppression. J. Immunol.178(10), 6158–6163 (2007).
   PubMedGoogle Scholar
• Aerts NE, Dombrecht EJ, Bridts CH et al. Simultaneous flow cytometric detection of basophil activation marker CD63 and intracellular phosphorylated p38 mitogen-activated protein kinase in birch pollen allergy. Cytometry B Clin. Cytom.76B(1), 8–17 (2008).
   Google Scholar
• Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat. Rev. Cancer6(2), 146–155 (2006).
   PubMed Web of Science ®Google Scholar
• Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood109(6), 2589–2596 (2007).
   PubMed Web of Science ®Google Scholar
• Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell118(2), 217–228 (2004).
   PubMed Web of Science ®Google Scholar
• Van Meter ME, Diaz-Flores E, Archard JA et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood109(9), 3945–3952 (2007).
   PubMedGoogle Scholar
• Kotecha N, Flores NJ, Irish JM et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell14(4), 335–343 (2008).
   PubMed Web of Science ®Google Scholar
• Lee AW, Sharp ER, O’Mahony A et al. Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J. Virol.82(7), 3702–3712 (2008).
   PubMed Web of Science ®Google Scholar
• Hotson AN, Hardy JW, Hale MB, Contag CH, Nolan GP. The T cell STAT signaling network is reprogrammed within hours of bacteremia via secondary signals. J. Immunol.182(12), 7558–7568 (2009).
   PubMed Web of Science ®Google Scholar
• Franceschini D, Paroli M, Francavilla V et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest.119(3), 551–564 (2009).
   PubMed Web of Science ®Google Scholar
• Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE. Astrocytic regulation of human monocytic/microglial activation. J. Immunol.181(8), 5425–5432 (2008).
   PubMed Web of Science ®Google Scholar
• Stitz J, Krutzik PO, Nolan GP. Screening of retroviral cDNA libraries for factors involved in protein phosphorylation in signaling cascades. Nucleic Acids Res.33(4), e39 (2005).
   PubMed Web of Science ®Google Scholar
• Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat. Methods3(5), 361–368 (2006).
   PubMed Web of Science ®Google Scholar
• Krutzik PO, Crane JM, Clutter MR, Nolan GP. High-content single-cell drug screening with phosphospecific flow cytometry. Nat. Chem. Biol.4(2), 132–142 (2008).
   PubMed Web of Science ®Google Scholar
• Lu SX, Alpdogan O, Lin J et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood112(13), 5254–5258 (2008).
   PubMedGoogle Scholar
• Dahl ME, Berson A, Lora J, Fuentes M. A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes. J. Pharmacol. Exp. Ther.327(3), 926–933 (2008).
   PubMed Web of Science ®Google Scholar
• Shachaf CM, Perez OD, Youssef S et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood110(7), 2674–2684 (2007).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med.250(6), 462–475 (2001).
   PubMed Web of Science ®Google Scholar
• Temesgen Z. Interleukin-2 for the treatment of human immunodeficiency virus infection. Drugs Today (Barc.)42(12), 791–801 (2006).
   PubMedGoogle Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist13(Suppl. 4), 16–25 (2008).
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J. Clin. Oncol.28(6), 1075–1083 (2010).
   PubMed Web of Science ®Google Scholar
• Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol.130(1), 28–37 (2010).
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res.14(20), 6674–6682 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia22(6), 1226–1233 (2008).
   PubMed Web of Science ®Google Scholar
• Varker KA, Kondadasula SV, Go MR et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin. Cancer Res.12(19), 5850–5858 (2006).
   PubMedGoogle Scholar
• Mortarini R, Vegetti C, Molla A et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin. Cancer Res.15(12), 4085–4094 (2009).
   PubMedGoogle Scholar
• Critchley -Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med.4(5), e176 (2007).
   Google Scholar
• O’Gorman WE, Dooms H, Thorne SH et al. The initial phase of an immune response functions to activate regulatory T cells. J. Immunol.183(1), 332–339 (2009).
   PubMed Web of Science ®Google Scholar
• Janetzki S, Britten CM, Kalos M et al. ‘MIATA’ – minimal information about T cell assays. Immunity31(4), 527–528 (2009).
   PubMed Web of Science ®Google Scholar
• Sachs K, Perez O, Pe’er D, Lauffenburger DA, Nolan GP. Causal protein-signaling networks derived from multiparameter single-cell data. Science308(5721), 523–529 (2005).
   PubMed Web of Science ®Google Scholar
• Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods125(1–2), 279–285 (1989).
   PubMed Web of Science ®Google Scholar
• Chao J, DeBiasio R, Zhu Z, Giuliano KA, Schmidt BF. Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CARD). Cytometry23(1), 48–53 (1996).
   PubMedGoogle Scholar
• Bandura DR, Baranov VI, Ornatsky OI et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem.81(16), 6813–6822 (2009).
   PubMed Web of Science ®Google Scholar
• Davis MM. A prescription for human immunology. Immunity29(6), 835–838 (2008).
   PubMed Web of Science ®Google Scholar